Treatment-resistant depression does not mean there are no remaining options. In psychiatry, it usually means the diagnosis, medication history, dose, duration, side effects, medical contributors, and functional impairment need to be reviewed more carefully before the next treatment step is chosen. For some California patients, that next step may include advanced options like Transcranial Magnetic Stimulation (TMS). For others, the priority may be medication optimization before TMS is started.
At Advanced Psychiatry Associates, treatment-resistant depression care connects Depression treatment, Medications Management, TMS, and, when appropriate, Spravato Esketamine Treatment.
What Treatment-Resistant Depression Means In Psychiatry
A patient may say, “My depression medication is not working,” but psychiatrists first ask whether the medication had a truly adequate trial. That means reviewing whether the antidepressant was taken consistently, at a therapeutic dose, for long enough to judge response. NIMH notes that antidepressants can take several weeks to work, and early changes in sleep, appetite, or energy may appear before mood fully improves.
APA’s article, The Advanced Psychiatric Algorithm for APA Treatment-Resistant Depression, is a strong companion resource because it explains how psychiatrists stage depression, define adequate trials, and decide when switching, augmentation, TMS, or esketamine should enter the plan.
Before TMS: What Psychiatrists Re-Check
Before moving into TMS, psychiatrists usually re-check the basics that can make depression appear resistant. This includes diagnosis accuracy, bipolar-spectrum symptoms, anxiety, ADHD, sleep disorders, substance use, medication adherence, medical conditions, and medication side effects.
APA’s article on Medical Causes of Depression is especially relevant when fatigue, brain fog, poor energy, or sleep problems are part of the picture. If insomnia is active, APA’s Sleep Psychiatry Approaches to Insomnia in Depression, Bipolar Disorder, ADHD may also help explain why sleep must be reviewed before calling a medication plan unsuccessful.
Switch vs. Augmentation: The Medication Decision Point
When antidepressant response is incomplete, psychiatrists often consider two main paths: switching medication or augmenting the current plan. Switching may make sense when there is little benefit, poor tolerability, or a mismatch between symptoms and medication effects. Augmentation may make sense when there is partial improvement but ongoing low mood, poor energy, insomnia, concentration problems, or loss of function.
APA’s Psychiatric Guide to SSRIs, SNRIs, and Atypical Antidepressants explains how psychiatrists choose between medication classes and adjust the plan based on symptom pattern, side effects, and follow-up response. This is the medication strategy that often happens before TMS is considered or while a patient is being evaluated for TMS.
Where TMS Fits In The Depression Treatment Plan
TMS is not simply “the next medication.” It is a noninvasive brain-stimulation treatment used for depression when standard medication approaches have not provided enough relief. NIMH’s brain stimulation resource explains that brain stimulation treatments work by activating or inhibiting brain activity using electricity or magnetic fields. APA’s TMS service page explains that TMS may be recommended for medication-resistant depression after comprehensive medical and psychiatric evaluation.
TMS can be used as part of a broader psychiatric plan rather than as a complete replacement for medication management. During TMS, psychiatrists may continue to monitor antidepressants, side effects, sleep, anxiety symptoms, mood changes, and safety concerns.
Medication Strategy Alongside TMS
A medication plan during TMS should stay structured. Patients should not stop antidepressants abruptly unless a psychiatrist provides a taper plan. APA’s article on Stopping Antidepressants Safely explains why discontinuation needs medical planning, especially when relapse risk is high.
If TMS response is partial, medication augmentation may still be considered. If medication side effects are limiting progress, the psychiatrist may adjust dose, timing, or medication class. If depression remains severe after multiple adequate trials, APA may also review advanced options such as Spravato Esketamine Treatment. The FDA’s Spravato prescribing information includes treatment-resistant depression as an adult indication, with dosing and monitoring requirements.
When To Schedule a TRD Medication Review
A treatment-resistant depression review is appropriate when two or more antidepressant trials have not produced enough improvement, side effects keep interrupting treatment, depression returns despite medication, or the diagnosis may need to be reconsidered. It is also urgent to seek immediate help if depression includes suicidal thinking, inability to function, severe insomnia, psychosis, or rapidly worsening impairment.
For patients searching for treatment resistant depression, depression medication not working, antidepressant augmentation, TMS for depression, medication options for depression, or TRD treatment, the best next step is a psychiatrist-led medication review that clarifies whether to optimize medication, move toward TMS, consider esketamine, or revise the diagnosis.
Schedule a treatment-resistant depression medication review with Advanced Psychiatry Associates if depression medication is not working, side effects are limiting progress, or you want to understand whether TMS should be part of your next-step treatment plan in California.
